Glycerophosphate

Other Names

1,2,3-Propanetriol, phosphate1-Glycerophosphate1-Glycerophosphorate1-Glycerophosphoric acid1-phosphoglycerol2,3-dihydroxypropyl dihydrogen phosphate3-Glycerophosphate3-phosphoglycerolalpha-Glycerophosphatealpha-Glycerophosphoratealpha-Glycerophosphoric acidalpha-Phosphoglycerolbeta-Glycerophosphatebeta-GlycerophosphorateD-Glycerol 1-phosphatedihydrogen alpha-glycerophosphateDL-alpha-Glycerol phosphateDL-alpha-GlycerophosphateDL-alpha-GlycerophosphorateDL-alpha-Glycerophosphoric acidDL-alpha-Glyceryl phosphateDL-Glycerol 1-phosphateDL-Glycerol 3-phosphateG3PGlycerol 1-(dihydrogen phosphate)Glycerol 1-phosphateGlycerol 2-phosphateGlycerol 3-phosphateGlycerol alpha-phosphateGlycerol dihydrogen phosphateGlycerol monophosphateGlycerol phosphateGlycerol-3-PGlycerophosphorateGlycerophosphoric acidGlycerophosphoric acid IIGlycerophosphoric acid, RacemicGlyceryl 1-phosphateGlyceryl 3-phosphateGlyceryl phosphateL-Glycerol 3-phosphatePhosphoric acid mono-(2,3-dihydroxy-propyl) estersn-glycerol 3-(dihydrogen phosphate)sn-Glycerol 3-phosphateβ-Glycerophosphate

Synopsis

Glycerophosphate: A Comprehensive Reference

1. Identity: Chemical Names, Structure, and Natural Sources

1.1 Chemical Identity and Nomenclature

Glycerophosphate (also known as glycerophosphoric acid in its free acid form, or glycerol phosphate) is an organic compound consisting of a glycerol backbone esterified to a phosphate group. The glycerophosphate component is derived from glycerol, a simple sugar alcohol, and phosphoric acid. Three principal positional isomers exist depending on which hydroxyl of glycerol carries the phosphate ester: α-glycerophosphate (glycerol-1-phosphate), β-glycerophosphate (glycerol-2-phosphate), and sn-glycerol-3-phosphate. Glycerol 3-phosphate (G3P), also known as sn-glycerol 3-phosphate, is a phosphorylated derivative of glycerol featuring a phosphate group esterified to the primary hydroxyl at the sn-3 position of the glycerol backbone, with the chemical formula C₃H₉O₆P and a molecular weight of 172.07 g/mol.

Magnesium glycerophosphate, for example, is an organic magnesium salt of glycerophosphoric acid; it exists as a mixture of magnesium salts of (RS)-2,3-dihydroxypropyl phosphate and 2-hydroxy-1-(hydroxymethyl)ethyl phosphate, which may be hydrated. The compound is a racemic mixture of the D- and L-glycerophosphate enantiomers. Sodium glycerophosphate is formally designated by IUPAC as disodium 2,3-dihydroxypropyl phosphate. It carries the CAS registry numbers 1334-74-3 and 1555-56-2 and EINECS designations 212-464-3 and 216-304-3; synonyms include sodium β-glycerophosphate, disodium glycerophosphate, and sodium 1-glycerophosphate.

The major natural glycerophospholipids — of which glycerophosphate is the structural backbone — include phosphatidylcholine (PtdCho), phosphatidylethanolamine (PtdEtn), phosphatidylserine (PtdSer), and phosphatidylinositol (PtdIns).

1.2 Natural Occurrence

Glycerophosphate is an organic compound naturally found in the body, and is usually used as a source of phosphate in the treatment of imbalance of phosphate metabolism. In its biologically active (R)-configuration, it serves as a central intermediate in eukaryotic metabolism, linking carbohydrate catabolism, lipid biosynthesis, and cellular energy transfer. As a naturally occurring endogenous metabolite, sn-glycerol-3-phosphate is present in virtually all living cells that contain phospholipid membranes.

Glycerophosphoric acid was discovered in the yolk of egg in 1846, and was but little known until 1893, when Robin drew attention to the large amount of partly oxidized phosphorus in the form of glycerophosphoric acid eliminated in the urine of some neurasthenics.

1.3 Common Salt Forms and Preparations

Glycerophosphate does not exist as a standalone supplement but is commercially and clinically encountered as mineral salts, each delivering both the mineral cation and the glycerophosphate anion:

Sodium glycerophosphate (NaGP): A water-soluble organic phosphate compound widely used in parenteral nutrition (PN) solutions to provide a bioavailable source of both sodium and phosphate.
Calcium glycerophosphate (CaGP): Calcium glycerophosphate (CaGP) can be described as a white, odorless, almost tasteless powder. It is recognized by the FDA as one of the calcium compounds safe and lawful for use in a dietary supplement or as a nutrient supplement.
Magnesium glycerophosphate: Magnesium glycerophosphate is a compound that joins magnesium, an essential mineral, with glycerophosphoric acid derived from plant-based glycerol. The pairing creates a white, water-soluble powder that is gentle on skin and teeth.
β-Glycerophosphate: A specific positional isomer extensively used in biochemical research and in chitosan-based thermosensitive hydrogels. The thermosensitive hydrogel has been prepared with chitosan and β-glycerophosphate or αβ-glycerophosphate, which is liquid at room temperature and solidifies into gel as temperature increases to body temperature.

In pharmaceutical formulations, sodium glycerophosphate is marketed under the trade name Glycophos® (Fresenius Kabi) as a concentrate for intravenous infusion. One of the more recognizable trade names for this compound is Glycerophos, although it can be found under several other brand names depending on the manufacturer and country of distribution. Calcium glycerophosphate is sold under the trade name Prelief® as an oral dietary supplement.

2. Traditional and Historical Use

2.1 Late Nineteenth-Century Origins

Historically, glycerophosphate salts (such as calcium or magnesium glycerophosphate) have been used since the late 19th and early 20th centuries as tonic agents and phosphate supplements to address deficiencies and support metabolic functions. Early anecdotal and clinical reports suggested benefits in convalescence, fatigue, and bone health, although these uses often predated modern clinical trial standards.

Writing in 1907, the British physician C. D. F. Phillips stated that "the glycerophosphates are now extensively employed and appear to have a distinct sphere of usefulness." Discovered in the yolk of egg in 1846, they were but little known till 1893, when Robin drew attention to the large amount of partly oxidized phosphorus in the form of glycerophosphoric acid eliminated in the urine of some neurasthenics. He administered compounds of this acid and found that they increase the general metabolism of both organic and inorganic matter, principally the latter, as shown by the augmented excretion of urea, chlorides, and sulfates, though not of uric acid or phosphates.

2.2 Therapeutic Indications in Historical Practice

The historical range of employment for glycerophosphates was wide: chronic gout, diabetes, phthisis, Bright's and even Addison's disease with nutritive decay, to improve the vital powers rather than to directly combat such maladies; similarly, any nervous breakdown, as in the aged or after acute illness; chlorosis, rachitis; chronic dyspepsia, especially with lessened acidity; and neuralgia, ataxia, sciatica, spermatorrhea, and neurasthenia generally when marked by depression, headache, and impaired mental and muscular strength.

In clinical practice, sodium glycerophosphate was often prescribed for patients suffering from exhaustion, convalescence after illness, and various forms of anemia. Its gentle yet effective action made it a popular remedy to support recovery and enhance overall vitality.

Sodium glycerophosphate is a compound that has played a significant role in medicinal nutrition since the early 20th century. Originally developed as a source of both sodium and phosphate, it was primarily utilized to address conditions of malnutrition, debility, and phosphate deficiency. These early clinical uses were largely empirical and were not supported by controlled experimental methods by modern standards. The transition from tonic medicine to clinical nutrition began more formally in the mid-to-late 20th century.

2.3 Transition to Modern Clinical Nutrition

Historically, sodium glycerophosphate's use in parenteral nutrition emerged as a safer and more stable alternative to inorganic phosphate salts, which can precipitate when mixed with calcium in intravenous formulations. Since the 1970s, sodium glycerophosphate has become a mainstay in clinical nutrition, especially for neonates, critically ill patients, and those unable to meet nutritional requirements orally or enterally.

3. Key Constituents and Established Mechanisms of Action

3.1 Dissociation and Phosphate Donation

Sodium glycerophosphate functions primarily as a phosphate donor. When introduced into the body, it is broken down into glycerol and inorganic phosphate. Glycerol is a simple sugar alcohol compound that is metabolized to provide energy, while the inorganic phosphate component is vital for numerous physiological functions. Phosphate is a crucial element for cellular energy production, muscle function, and overall cellular health. It plays a significant role in the formation of ATP (adenosine triphosphate), the primary energy currency of cells. ATP is essential for various biochemical processes, including muscle contractions, nerve signal transmission, and biochemical synthesis pathways.

Additionally, phosphate is a component of DNA, RNA, and phospholipids, which are critical for genetic information transfer and maintaining cellular membrane integrity.

3.2 The Glycerol-3-Phosphate Shuttle

The endogenous metabolite sn-glycerol-3-phosphate (G3P) operates a fundamental shuttle system linking cytosolic and mitochondrial energy metabolism. The glycerol-3-phosphate shuttle is a mechanism used in skeletal muscle and the brain that regenerates NAD+ from NADH, a by-product of glycolysis. NADH is a reducing equivalent that stores electrons generated in the cytoplasm during glycolysis.

Mitochondrial sn-glycerol 3-phosphate dehydrogenase (mGPDH; EC 1.1.5.3; gene symbol GPD2) is an important link between cytosolic and mitochondrial energy transduction. mGPDH is a ubiquinone-linked flavoprotein embedded in the outer leaflet of the mitochondrial inner membrane that transfers reducing equivalents directly from glycerol 3-phosphate into the electron transport chain. Its oxidation to dihydroxyacetone phosphate (DHAP) by mGPDH, and the subsequent reduction of DHAP back to glycerol 3-phosphate by soluble cytosolic GPDH, regenerates NAD+ consumed during glycolysis. This cyclic process of transferring reducing equivalents from cytosolic NADH into the mitochondrial respiratory chain is known as the glycerol phosphate shuttle.

The glycerol phosphate shuttle, also known as the glycerophosphate shuttle, shuttles electrons to mitochondrial carriers in the oxidative phosphorylation pathway from cytosolic NADH. This shuttle relies on mitochondrial glycerol-3-phosphate dehydrogenase (mGPDH). This is also a common process for the cell to regenerate cytosolic NAD+ for other processes.

Another Ca²⁺-sensitive booster of mitochondrial ATP synthesis is the glycerol-3-phosphate shuttle (G3PS), whose role in neuronal energy supply has remained elusive. Essential components of G3PS are expressed in hippocampal neurons. Single neuron metabolic measurements in primary hippocampal cultures derived from rat pups reveal only moderate, if any, constitutive activity of G3PS. However, during electrical activity, neurons fully rely on G3PS when the malate-aspartate shuttle (MAS) and mitochondrial calcium uniporter (MCU) are unavailable.

3.3 Role in Lipid Biosynthesis

G3P is primarily synthesized in the cytosol through the reversible reduction of dihydroxyacetone phosphate (DHAP), a glycolytic intermediate, by NAD⁺-dependent glycerol-3-phosphate dehydrogenase (GPD1), consuming NADH and thereby contributing to cytosolic redox balance. Alternatively, it can be generated from free glycerol via phosphorylation by glycerol kinase, a pathway prominent in liver and kidney tissues during lipolysis or dietary glycerol uptake.

Glycerophosphate has a fundamental role in cell membrane and main organ tissue constitution, in particular brain tissues. In fact, glycerophosphate operates in the phospholipid synthesis. Phospholipids are complex lipids that participate in the constitution of cell membranes and the tissues of the main organs.

3.4 pH Buffering Activity

As a buffering agent, sodium glycerophosphate helps maintain the pH balance in the body. In the stomach, it can neutralize excess acid, providing relief from symptoms of acid reflux and heartburn. In medical formulations, it helps stabilize the pH of solutions, ensuring the efficacy and safety of the pharmaceutical product.

3.5 Effect on Vascular Smooth Muscle Cells (Research Context)

Research using β-glycerophosphate as a phosphate donor in cell culture models has yielded findings with relevance to vascular physiology. The phosphate donor β-glycerophosphate not only promotes a more oxidative phenotype with increased basal respiration and mitochondrial ATP production rates, as well as changes in mitochondrial fuel choice, but also increases proton leak and thus reduces the coupling efficiency of baseline metabolism. β-Glycerophosphate modifies key parameters of mitochondrial function and cellular bioenergetics in vascular smooth muscle cells (VSMCs) that may contribute to the onset of phenotypical transdifferentiation and calcification. These observations advance the understanding of the role of energy metabolism in VSMC physiology and pathophysiology of vascular calcification during hyperphosphatemia. These findings are from in vitro cell culture models and should not be interpreted as direct evidence for physiological effects of supplemental glycerophosphate at clinical doses.

4. Scientific Evidence by Area of Use

4.1 Parenteral Nutrition and Phosphate Repletion

Evidence strength: Moderate to strong for clinical utility in parenteral nutrition; well-established in neonatal and intensive care settings.

The most robustly supported clinical use of glycerophosphate (specifically as sodium glycerophosphate) is as a phosphate source in parenteral nutrition (PN), where it resolves the incompatibility of inorganic calcium and phosphate salts in solution. The solubility of inorganic calcium and phosphate in parenteral solutions can be complicated in pediatrics due to the dosing of calcium and phosphorus at the saturation point. Studies have tested the solubility of sodium glycerophosphate (NaGP) with calcium gluconate in pediatric parenteral nutrition solutions. It has been concluded that NaGP should replace sodium phosphate in PN solutions, as this would eliminate the concern of calcium and phosphorus precipitation and the need for saturation curves.

Preterm infants require higher calcium and phosphate intake than term infants to facilitate adequate bone growth, but this is rarely met in parenteral nutrition solutions because of the limited solubility of calcium and phosphate. Studies have demonstrated that the use of NaGP significantly increased the compatibility of calcium and phosphate when neonatal PN was composed of commonly used components and concentrations, even after 10-day storage.

A study evaluating the treatment of neonatal hypophosphataemia enrolled nineteen very low birthweight infants (mean gestational age 28 weeks). These very low birthweight infants were parenterally fed nutrition solutions containing inorganic calcium and phosphorus salts; all infants had hypophosphataemia. Plasma concentrations were maintained between 1.5 mmol/l and 2.2 mmol/l. Plasma phosphorus concentrations reached 1.5 mmol/l or greater in three patients after 12 hours, in a further nine patients after 36 hours, and in all patients by 60 hours. Changes in plasma calcium concentrations were not significant.

A larger retrospective cohort study (n = 402 newborns in a neonatal intensive care unit) compared outcomes between neonates receiving sodium glycerophosphate versus inorganic phosphate in PN. This retrospective cohort study enrolled 402 newborns admitted to the NICU between January 2019 and September 2021: 205 received sodium glycerophosphate as parenteral nutrition, while 197 received inorganic phosphate. Growth parameters, calcium and phosphate content, alkaline phosphatase (ALP), and morbidities were compared. During the first 4 weeks, the calcium and phosphate contents of parenteral nutrition were significantly higher in the sodium glycerophosphate vs. inorganic phosphate group, while growth parameters did not differ significantly between groups.

A retrospective cohort study published in the Journal of Pediatrics (2022) evaluated NaGP in extremely low birthweight (ELBW) infants. The study evaluated the clinical effect of sodium glycerophosphate (NaGP) in parenteral nutrition solutions on mineral metabolism in ELBW infants. NaGP was introduced for use in place of potassium phosphate (K₃PO₄) in January 2018; this retrospective cohort study included 95 ELBW infants treated with K₃PO₄ between January 2015 and December 2017, and 77 infants treated with NaGP between August 2018 and January 2021. The use of NaGP instead of K₃PO₄ significantly increased Ca and P intake, but intakes remained below the recommended range (Ca, 64–140 mg/kg/day; P, 50–108 mg/kg/day).

Compared with inorganic salts, organic calcium and phosphate in parenteral nutrition solutions have higher compatibility and lower precipitation risks. The use of sodium glycerophosphate allows greater concentrations of calcium and phosphorus to be administered via parenteral nutrition, as either phosphate from infused glycerophosphate is directly available or phosphorus becomes displaced from the intracellular pool.

4.2 Dental Health — Enamel Remineralization and Caries Prevention

Evidence strength: Moderate for in situ and in vitro studies; limited but emerging for clinical trials, particularly in pediatric populations.

On direct interaction with hydroxyapatite, a combination of calcium glycerophosphate and sodium monofluorophosphate has been found to decrease acid formation and enhance remineralization of the enamel due to increased uptake of fluoride in the non-alkaline-soluble form; moreover, calcium glycerophosphate buffers the pH of the plaque and increases plaque Ca²⁺ and PO₄³⁻ levels, thus providing a cariostatic effect.

A published in situ study examined low-fluoride dentifrices supplemented with CaGP. The addition of 0.25% CaGP improved the remineralization potential of low-fluoride toothpastes, and sodium fluoride as source of fluoride yielded the best results (p<0.001) as evidenced by hardness analysis. The 1100 ppm F toothpaste provided higher presence of fluoride in the enamel after remineralization (p<0.001). Toothpastes with 500 ppm F (NaF or MFP) and CaGP showed similar remineralization potential to 1100 ppm F toothpaste. Toothpastes containing 500 ppm F associated with CaGP, with both fluoride sources (NaF or MFP), showed a potential of remineralization similar to commercial toothpaste. Although there is a need for confirmation in the clinical setting, these results point to an alternative for improving the risk-benefit relationship between fluorosis and dental caries in small children.

A double-blind, randomized controlled trial assessed the clinical efficacy of low-fluoride dentifrices (LFDs) supplemented with CaGP or sodium trimetaphosphate (TMP) on the progression of dental caries in the deciduous dentition. This double-blind, randomized controlled trial assessed the clinical efficacy of LFDs supplemented with calcium glycerophosphate (CaGP) or sodium trimetaphosphate (TMP) on the progression of dental caries in the deciduous dentition. Children (average age 48 months old) from two Brazilian cities were randomly assigned into 3 groups according to the dentifrice: 500 ppm F plus 1% TMP (n=206), 500 ppm F plus 0.25% CaGP (n=201), and 1100 ppm F (n=193). Clinical exams were performed at baseline and 18 months after dentifrices started to be used.

An in vitro study evaluated the remineralization effect of CaGP in fluoride mouth rinse on permanent enamel eroded by soft drinks. Forty sound permanent premolars were embedded in self-curing acrylic resin and immersed in Coca-Cola to create erosive lesions. The teeth were divided into four groups: artificial saliva; sodium fluoride; sodium fluoride + sodium monofluorophosphate; and sodium monofluorophosphate + CaGP. Fluoride mouth rinse with CaGP and fluoride mouth rinses showed similar efficacies in remineralizing eroded permanent tooth enamel. However, further clinical studies with a larger sample size are needed to validate this finding and evaluate the effectiveness and efficiency of CaGP in dental health.

Phosphate salts such as sodium trimetaphosphate (TMP), sodium hexametaphosphate (SHMP), and calcium glycerophosphate (CaGP) have been incorporated into topical fluoride formulations as interfacial modifiers. A 2026 narrative review in Frontiers in Oral Health critically examined mechanisms, experimental evidence, and clinical data on polyphosphate systems for early enamel carious lesions across in vitro, in situ, and in vivo human studies. Overall, the body of dental evidence for CaGP is promising but not yet sufficiently large to establish definitive clinical recommendations.

4.3 Mineral Supplementation: Magnesium and Calcium Delivery

Evidence strength: Preliminary to moderate for superior bioavailability of organic versus inorganic mineral salts; specific clinical outcome data for glycerophosphate forms remain limited.

Magnesium supplements come in a variety of forms, including inorganic salts (oxide, sulfate, etc.) and organic salts (citrate, glycinate, malate, glycerophosphate, etc.). Studies on bioavailability show that organic salts are more bioavailable than inorganic salts.

A bioavailability study using the Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) and dissolution testing compared the bioavailability of magnesium glycerophosphate formulations with inorganic forms. The supplement tested contained both organic and inorganic Mg²⁺ salts: one tablet consisting of 248.72 mg Mg oxide (corresponding to 149 mg Mg) and 380.72 mg Mg glycerophosphate (containing 12.37% Mg, corresponding to 47 mg Mg). The selected supplement with one of the highest predicted bioavailability differs from other formulations as it contains both inorganic (Mg oxide) and organic (Mg glycerophosphate) magnesium salts, while the supplement with the worst predicted bioavailability consists of only inorganic magnesium (Mg oxide).

The disadvantage of organic sources of magnesium holds that, although they have a higher solubility, they provide only limited levels of elementary magnesium in contrast to inorganic salt which offers a high loading of elementary magnesium. This trade-off between per-unit elemental content and absorption efficiency is a key practical consideration.

Calcium glycerophosphate has been selected for its excellent calcium bioavailability. Studies in low-birth-weight infants and piglets showed that CaGP is as effective as calcium gluconate as a source of calcium in total parenteral nutrition (TPN) solutions and could be used to prevent undermineralized bones in low-birth-weight infants.

Glycerophosphate offers a potentially more gentle and better-absorbed alternative to inorganic phosphate salts, making it attractive for use in nutritional formulations. However, the body of contemporary, large-scale clinical trials on glycerophosphate is limited; available evidence and its historical use support its safety and efficacy as a nutritional supplement in appropriate contexts.

4.4 Cardiovascular Effects: Ventricular Premature Beats

Evidence strength: Very preliminary; based on a single small observational report.

When compared with baseline, the mean number of ventricular premature beats (VPBs) fell from 982 to 416 per 24 hours during magnesium glycerophosphate therapy (P < 0.02). The results of this study suggest that treatment with magnesium glycerophosphate is associated with a decrease in premature ventricular contractions (PVCs). This observation is reported in the context of magnesium's established role in cardiac electrophysiology. The strength of this evidence is very low; a single small study cannot establish causation, and confirmation in larger controlled trials is required.

4.5 Muscle and Neurological Effects

Evidence strength: Extremely preliminary; no robust human clinical trial data specific to glycerophosphate form for these indications.

Approximately 27% of magnesium in the body is found in muscles, which makes sense considering that — while calcium is needed for muscle contraction — magnesium is needed for muscle relaxation. Analyses of clinical research suggest that magnesium supplementation has not decreased the frequency or intensity of skeletal muscle cramps compared to placebo. However, a different result was seen in a study on the effects of magnesium glycerophosphate on spasticity — a condition in which certain muscles are continuously contracted, causing stiffness or tightness of the muscles. Details of that spasticity study were not independently verifiable in peer-reviewed sources during research for this article, and the claim should be interpreted with caution.

Two recent reviews assessed the therapeutic applications of magnesium in cognitive health. A systematic review and meta-analysis concluded with moderate confidence that serum magnesium has a U-shaped association with dementia and cognitive impairment. Another review stated that maintaining adequate magnesium levels is preventive of dementia and Alzheimer's disease, especially in older adults and individuals with metabolic risk factors. The studies analyzed in these reviews were heterogeneous regarding supplementation, and conclusions could not be drawn about the best supplement. This may be due to differences in forms and doses used, which affect bioavailability. These findings pertain to magnesium status generally and cannot be attributed specifically to glycerophosphate without form-specific human trial data.

5. Body Systems Associated with Glycerophosphate

Skeletal system: Glycerophosphate salts deliver both calcium/magnesium and phosphate, both essential for hydroxyapatite formation in bone. Clinical evidence from neonatal PN studies supports prevention of metabolic bone disease of prematurity.
Oral/dental system: Calcium glycerophosphate buffers plaque pH, increases plaque mineral ion concentrations, and potentiates fluoride-mediated enamel remineralization.
Cellular energy metabolism: As a central intermediate in eukaryotic metabolism, sn-glycerol-3-phosphate links carbohydrate catabolism, lipid biosynthesis, and cellular energy transfer.
Nervous system: The glycerol-3-phosphate shuttle is a Ca²⁺-sensitive booster of mitochondrial ATP synthesis whose role in neuronal energy supply has been demonstrated in hippocampal neurons.
Cardiovascular system: The magnesium cation in magnesium glycerophosphate influences cardiac electrophysiology; at the biochemical level, β-glycerophosphate at supraphysiological concentrations has been shown to affect vascular smooth muscle cell mitochondrial function in vitro.
Gastrointestinal system: Calcium and sodium glycerophosphate function as antacid/buffering agents, neutralizing gastric acid and relieving acid-related discomfort. The primary target of calcium glycerophosphate includes the alleviation of conditions related to acid imbalance in the body, such as heartburn, acid reflux, and dental erosion.

6. Dosage Forms and Reported Study Dosages

6.1 Parenteral (Intravenous) Administration

According to the official product information for sodium glycerophosphate 21.6% concentrate for infusion, up to 120 ml (and corresponding calcium amounts) can be added to 1000 ml of specific amino acid solutions. Up to 10 ml (with 10 mmol of calcium) can be added to other PN base solutions. Sodium glycerophosphate concentrate must not be given undiluted.

In the neonatal study by the Journal of Pediatrics (2022), use of NaGP significantly increased Ca and P intake vs. K₃PO₄, but intakes remained below the recommended range of Ca 64–140 mg/kg/day and P 50–108 mg/kg/day.

In the pediatric PN compatibility study, five PN solutions were compounded by adding calcium gluconate at 10, 20, 30, 40, and 50 mEq/L with corresponding concentrations of NaGP at 10, 20, 30, 40, and 50 mmol/L.

In a separate neonatal PN solubility study, PN solutions were composed of calcium gluconate at 50 mEq/L and sodium glycerophosphate at 25 mmol/L, with 1% or 4% amino acid and 10% or 20% dextrose.

6.2 Oral Supplement Dosages

In the in situ dental study, children (average age 48 months) were assigned to toothpastes containing 500 ppm F plus 0.25% CaGP, or 500 ppm F plus 1% TMP, or 1100 ppm F as a control, over an 18-month period.

In the in situ enamel remineralization study, a dentifrice concentration of 0.25% CaGP was used to improve the remineralization potential of low-fluoride toothpastes.

In the magnesium bioavailability study, a supplement containing Mg glycerophosphate was studied with a dose corresponding to 47 mg elemental Mg per tablet from the glycerophosphate fraction, with a total elemental magnesium content of 196 mg per tablet when combined with the magnesium oxide component.

7. Safety Considerations and Interactions

7.1 Contraindications

The official product labeling for sodium glycerophosphate 21.6% concentrate for solution for infusion states that it should not be given to patients in a state of dehydration, with hypernatraemia, hyperphosphataemia, severe renal insufficiency, or shock.

Contraindications for using sodium glycerophosphate include existing hyperphosphatemia, severe kidney dysfunction, and certain types of metabolic bone diseases where phosphate metabolism is already compromised. Patients with a history of hypersensitivity to phosphate-containing compounds should also avoid this medication.

For calcium glycerophosphate specifically: elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium-phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues. Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia, hypoparathyroidism, or severe renal impairment. Individuals with hypercalcemia or kidney stones should avoid calcium glycerophosphate, as it can exacerbate these conditions.

7.2 Renal Considerations

Patients with renal impairment should use sodium glycerophosphate with caution. Regular monitoring of renal function and phosphate levels is essential to prevent complications. Drugs that affect renal function, such as diuretics or certain types of antibiotics, can also interact with sodium glycerophosphate. Since the kidneys play a crucial role in regulating phosphate levels, any medication that impacts renal function can influence the effectiveness and safety of this compound.

7.3 Electrolyte Monitoring

Sodium glycerophosphate can cause electrolyte imbalances, particularly hypernatraemia and hyperphosphataemia. Regular monitoring of electrolyte levels is necessary to prevent adverse effects. The phosphate status of all patients receiving sodium glycerophosphate should be monitored regularly.

7.4 Observed Drug Interactions

No interactions with other drugs have been observed for Glycophos (sodium glycerophosphate for infusion), but a moderate fall in serum phosphate can be seen during carbohydrate infusions.

Antacids containing aluminum or magnesium can bind to phosphate in the gastrointestinal tract, reducing the absorption and effectiveness of orally administered sodium glycerophosphate.

Vitamin D can increase calcium absorption, which may lead to hypercalcemia when used concurrently with sodium glycerophosphate. Close monitoring of calcium and phosphate levels is necessary.

Some diuretics, such as loop and thiazide diuretics, can affect electrolyte balance. Their concurrent use with sodium glycerophosphate should be monitored to prevent complications.

For calcium glycerophosphate: calcium supplements in general can reduce the absorption of bisphosphonates, a class of drugs used to treat osteoporosis. To maximize the efficacy of both bisphosphonates and calcium glycerophosphate, it is advisable to space out their administration times.

7.5 Gastrointestinal Tolerability

While calcium glycerophosphate is generally considered safe, it is not without its side effects and contraindications. Some individuals may experience gastrointestinal discomfort, such as bloating or constipation, especially when taken in large doses. In rare cases, allergic reactions may occur, manifesting as hives, itching, or swelling.

No adverse effects related to glycerophosphate have been reported in the product labeling for Glycophos®. Glycophos® is generally safe and very well-tolerated in recommended doses.

7.6 Use During Pregnancy and Lactation

The safety of sodium glycerophosphate during pregnancy and lactation has not been established in controlled studies; it should be used only if the potential benefits outweigh the risks, and under the supervision of a healthcare provider. Per the Glycophos® product information, the requirements for phosphate in a pregnant woman are slightly increased compared to non-pregnant women, and no adverse events are to be expected when Glycophos is administered during pregnancy. No adverse effects are expected for a nursing child.

8. Summary of Evidence Landscape

Glycerophosphate salts occupy a well-established position in clinical parenteral nutrition, where sodium glycerophosphate is supported by multiple controlled and cohort studies in neonates and premature infants. The evidence for calcium glycerophosphate in dental remineralization is moderate and growing, with in situ human studies and at least one randomized controlled trial supporting its utility as an adjunct to low-fluoride fluoride dentifrices. The evidence for systemic benefits of oral magnesium glycerophosphate supplementation — including cardiovascular, muscular, and neurological claims — is preliminary and largely extrapolated from general magnesium physiology rather than glycerophosphate-specific trials. The body of contemporary, large-scale clinical trials on glycerophosphate is limited. More targeted research is warranted to further establish its specific benefits and optimal applications in human health.

References

Health Conditions

Health conditions that Glycerophosphate may help support.

No conditions available.

Body Systems

Body systems that Glycerophosphate may help support.

No body systems available.